FFTY - ETF AI Analysis
Top Page
Innovator IBD 50 ETF (FFTY)
FFTY’s rating suggests it is a relatively solid but somewhat risky growth-focused ETF, driven by several strong holdings with good business momentum and earnings trends. Standout positions like Okeanis Eco Tankers, Natera, Kiniksa Pharmaceuticals, WisdomTree, and Hinge Health support the fund’s quality through robust revenue growth, positive earnings sentiment, and favorable technical or strategic developments. However, weaker names such as Rubrik and Eton Pharmaceuticals, along with common issues like profitability challenges, high leverage, and some overbought or bearish technical signals, add risk, with the main concern being the fund’s exposure to multiple companies facing financial and valuation pressures.
FFTY vs. SPDR S&P 500 ETF (SPY)
- AUM
- 62.66M
- Region
- North America
- Expense Ratio
- 0.80%
- Beta
- 1.36
- Issuer
- CapForce
- Inception Date
- Apr 09, 2015
- Dividend Yield
- 1.45%
- Asset Class
- Equity
- Index Tracked
- IBD 50 TR
FFTY Summary
Innovator IBD 50 ETF (FFTY) is a U.S. stock fund that follows the IBD 50 Index, a list of 50 fast-growing companies picked for strong sales and earnings. It leans heavily toward health care and technology, and includes well-known names like Advanced Micro Devices (AMD) and Guardant Health. Investors might consider FFTY if they want focused exposure to growth stocks and are looking to add potential high-return companies to their portfolio. However, this ETF can be quite volatile and may go up and down more than the overall market, especially during market downturns.
How much will it cost me?
The Innovator IBD 50 ETF (FFTY) has an expense ratio of 0.8%, which means you’ll pay $8 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on selecting top-performing growth stocks rather than passively tracking a broad index.
What would affect this ETF?
The Innovator IBD 50 ETF (FFTY), with its focus on growth stocks and heavy exposure to technology and healthcare sectors, could benefit from advancements in innovation, favorable economic conditions, and increased investor interest in high-growth industries. However, it may face challenges from rising interest rates, regulatory changes, or economic slowdowns, which could negatively impact smaller-cap stocks and growth-focused companies. Its U.S.-centric portfolio also makes it sensitive to domestic market trends and policies.
FFTY Top 10 Holdings
FFTY is leaning hard into U.S. growth, with a clear tilt toward health care innovators and a dash of tech. Eton Pharmaceuticals and Okeanis Eco Tankers have been standout risers, giving the fund a strong tailwind, while Natera, Hinge Health, and Guardant Health add more steady, growth-focused fuel from the medical side. Cloudflare and Rubrik bring the cloud and cybersecurity theme into the mix, though their profitability struggles can occasionally weigh on sentiment. Overall, a concentrated bet on cutting-edge U.S. names, with health care in the driver’s seat.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 HALO | Halozyme | 4.28% | $2.68M | $13.90B | 82.75% | 73Outperform |
 KNSA | Kiniksa Pharmaceuticals | 3.93% | $2.46M | $6.20B | 105.69% | 72Outperform |
 NTRA | Natera | 3.87% | $2.43M | $57.57B | 119.84% | 73Outperform |
 ECO | Okeanis Eco Tankers Corp. | 3.97% | $2.49M | $3.41B | 164.59% | 78Outperform |
 RBRK | Rubrik, Inc. Class A | 3.54% | $2.22M | $23.51B | 46.87% | 50Neutral |
 ERO | Ero Copper | ― | ― | ― | ― | 76Outperform |
 HNGE | Hinge Health, Inc. Class A | 3.38% | $2.12M | $8.39B | 110.96% | 70Outperform |
 AMD | Advanced Micro Devices | 3.19% | $2.00M | $878.35B | 130.84% | 73Outperform |
 MU | Micron | 3.15% | $1.97M | $1.02T | 347.13% | 79Outperform |
 ZETA | Zeta Global Holdings Corp | 3.15% | $1.97M | $8.16B | 82.38% | 67Neutral |
FFTY Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FFTY, the sentiment is Negative. The current price of 32.44 is below the 20-day moving average (MA) of 34.76, below the 50-day MA of 35.69, and below the 200-day MA of 37.68, indicating a bearish trend. The MACD of -0.71 indicates Positive momentum. The RSI at 29.51 is Positive, neither overbought nor oversold. The STOCH value of 11.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FFTY.
FFTY Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FFTY | $32.44 | $38.00(17.14% Upside) | $62.66M | 0.80% | 66Neutral |
 BAMD | $33.48 | $37.52(12.06% Upside) | $98.24M | 0.87% | 70Outperform |
 BUZZ | $35.01 | $51.89(48.22% Upside) | $91.02M | 0.76% | 65Neutral |
 STNC | $36.68 | $42.24(15.15% Upside) | $92.04M | 0.85% | 68Neutral |
 SOVF | $31.34 | $37.09(18.34% Upside) | $88.77M | 0.75% | 70Neutral |
 PFOE | $22.25 | $28.55(28.33% Upside) | $88.32M | 0.59% | 72Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FFTY | Innovator IBD 50 ETF | 32.44 | -4.94 | -13.22% | |
| BAMD | Brookstone Dividend Stock ETF | 33.48 | 3.45 | 11.50% | |
| BUZZ | VanEck Social Sentiment ETF | 35.01 | -0.70 | -1.96% | |
| STNC | Stance Equity ESG Large Cap Core ETF | 36.68 | 3.78 | 11.49% | |
| SOVF | Sovereign's Capital Flourish Fund | 31.34 | 1.55 | 5.20% | |
| PFOE | Pathfinder Focused Opportunities ETF | 22.25 | -2.61 | -10.48% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.